ARS Investment Partners LLC Has $38.87 Million Position in Biohaven Ltd. (NYSE:BHVN)

ARS Investment Partners LLC increased its position in Biohaven Ltd. (NYSE:BHVN) by 1.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,040,712 shares of the company’s stock after purchasing an additional 10,473 shares during the period. Biohaven makes up 3.5% of ARS Investment Partners LLC’s investment portfolio, making the stock its 6th largest holding. ARS Investment Partners LLC owned about 1.03% of Biohaven worth $38,871,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the business. nVerses Capital LLC bought a new stake in Biohaven during the third quarter worth $50,000. Values First Advisors Inc. purchased a new position in shares of Biohaven in the 3rd quarter worth approximately $78,000. US Bancorp DE increased its position in shares of Biohaven by 57.1% during the third quarter. US Bancorp DE now owns 2,173 shares of the company’s stock valued at $109,000 after acquiring an additional 790 shares during the last quarter. KBC Group NV lifted its holdings in Biohaven by 24.5% during the third quarter. KBC Group NV now owns 2,250 shares of the company’s stock worth $112,000 after acquiring an additional 443 shares during the period. Finally, Venturi Wealth Management LLC boosted its holdings in shares of Biohaven by 19.1% in the 3rd quarter. Venturi Wealth Management LLC now owns 3,117 shares of the company’s stock worth $156,000 after buying an additional 500 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Insider Transactions at Biohaven

In other news, Director John W. Childs acquired 29,000 shares of Biohaven stock in a transaction dated Monday, December 30th. The stock was purchased at an average cost of $35.94 per share, with a total value of $1,042,260.00. Following the completion of the purchase, the director now directly owns 2,368,741 shares in the company, valued at approximately $85,132,551.54. This trade represents a 1.24 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 16.00% of the company’s stock.

Biohaven Stock Up 4.8 %

Shares of BHVN opened at $37.57 on Tuesday. The company has a market capitalization of $3.80 billion, a P/E ratio of -4.02 and a beta of 1.29. Biohaven Ltd. has a twelve month low of $26.80 and a twelve month high of $62.21. The firm has a 50 day moving average of $41.03 and a 200 day moving average of $42.40.

Biohaven (NYSE:BHVN) last issued its earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). On average, sell-side analysts expect that Biohaven Ltd. will post -8.85 EPS for the current year.

Wall Street Analyst Weigh In

BHVN has been the subject of a number of research reports. Sanford C. Bernstein increased their target price on shares of Biohaven from $55.00 to $66.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 24th. Robert W. Baird increased their target price on Biohaven from $58.00 to $60.00 and gave the stock an “outperform” rating in a research report on Monday, September 23rd. Piper Sandler lifted their price target on Biohaven from $66.00 to $76.00 and gave the company an “overweight” rating in a research report on Monday, September 23rd. JPMorgan Chase & Co. raised their target price on Biohaven from $55.00 to $68.00 and gave the stock an “overweight” rating in a research note on Thursday, October 3rd. Finally, Leerink Partners lifted their price objective on shares of Biohaven from $55.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd. Thirteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $63.00.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.